top of page


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
13/10/2026 SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D Legacy Healthcare received US FDA Breakthrough Therapy Designation for CINAINU® (LH-8) in alopecia areata Evergreen Therapeutics received FDA Fast Track Designation for EG-501 in NPSLE-CI SAB BIO received US FDA Fast Track Designation for SAB-142 in stage 3 T1D (Ref) SAB Biotherapeutics’ SAB-142 received US FDA Fast Track Designation for treatment of new-onset Stage 3 Type 1 diabetes (T1D). T
decodeMR Team
Oct 151 min read


Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
22/04/2026 Roche announced Phase 3 data for fenebrutinib in RMS Johnson & Johnson announced Phase 3 data for nipocalimab in gMG Sanofi's Tzield approved in the US to delay the onset of stage 3 T1D in young children Roche announced Phase 3 data for fenebrutinib in RMS (Ref) Roche announced new positive data from the Phase 3 FENhance 1 and 2 studies, Which investigated fenebrutinib (BTK inhibitor) for the treatment of patients with Relapsing Multiple Sclerosis (RMS). FENhance 1
decodeMR Team
Apr 222 min read
bottom of page